Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial.

In the past, immunogenicity of hepatitis A and B vaccines needed to be questioned in persons of advanced age, especially in those of 40 years and older. We performed a comparative multicenter prospective and retrospective study with the combined hepatitis A and B vaccine Twinrix to identify factors influencing the results of the vaccination in a population of all age groups. Out of 489 subjects enrolled, 241 were vaccinated in a prospective study (group 1) and 248 subjects in a retrospective study (group 2) in 17 German centers with median age of 40.1 (14-79) years. Following three applications of the combined hepatitis A/B vaccine we found 96.2% with protective antibodies against HAV and 88.7% were protected against HBV. With increasing age the subjects developed decreasing anti-HBs antibody levels whereas the seroprotection rate was significantly reduced by age (p < 0.05) in the retrospective study group only. Subjects with arterial hypertension and thyroid disease showed significantly decreased protection rates. The timing of the HBV antibody control seems to be important especially in low-responders because protective antibodies may drop below the detection limit within some month. The combined hepatitis A and B vaccine Twinrix proved to be highly effective against HBV, although antibody concentrations and seroprotection rates decreased with increasing age.
AuthorsBernd Wolters, Tobias Müller, R Stefan Ross, Ralf Clauberg, Uwe Werfel, Hedwig Roggendorf, Cornelius Siggelkow, Thomas Hausen, Michael Roggendorf
JournalHuman vaccines (Hum Vaccin) Vol. 5 Issue 4 Pg. 248-53 (Apr 2009) ISSN: 1554-8619 [Electronic] United States
PMID19276678 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
  • Vaccines, Combined
  • twinrix
  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Female
  • Germany
  • Hepatitis A (immunology, prevention & control)
  • Hepatitis A Antibodies (blood)
  • Hepatitis A Vaccines (immunology)
  • Hepatitis B (immunology, prevention & control)
  • Hepatitis B Antibodies (blood)
  • Hepatitis B Vaccines (immunology)
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Retrospective Studies
  • Time Factors
  • Vaccines, Combined (immunology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: